中国中药(00570.HK)股价今日盘中大跌逾5%,引发市场广泛关注。有分析指出,公司私有化进程遇阻以及南向资金连续卖出均是导致其股价下跌的主要原因。
据悉,中国中药此前筹划被国药集团私有化,拟以每股4.6港元的价格完成。但最新公告显示,由于预计无法在今年10月18日前获得尚未获得的境外直接投资批准,公司私有化进程受阻,目前正寻求延期。公司私有化前景不明朗,引发投资者担忧。
与此同时,南向资金连续5个交易日净卖出中国中药股票,仅昨日即净卖出312.6万股,使公司股价承压。南向资金撤离加剧了对中国中药的抛售力道。分析人士指出,公司私有化进程受阻以及资金流出,共同导致公司今日出现盘中重挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.